In parallel studies, we determined that CD8+CD56+ immune cells are capable of killing autologous and allogeneic cancer cells by mechanisms that are known to mediate the cytotoxicity of natural killer (NK) cells as well as through T-cell receptor (TRC) engagement (manuscript in preparation). Here, CD8A is linked to cancer.